A total of 172 adults were screened, of which 136 were enrolled in the study (Figure 2). Study documentation did not capture the reasons why 36 participants from the screening were not enrolled. Of the enrolled population, 129 participants reconfirmed eligibility upon study product receipt. Of these, 102 participants were included in the mITT population as they used the study product at least once and completed at least one post-baseline QoL questionnaire. Two participants from the mITT population discontinued the study due to ‘early termination’ for non-compliance reasons after using the study product (Supplemental Results Section 1). Data up to the time of discontinuation were included in the mITT analysis. Figure 2 also shows the number of participants remaining from day 1 through day 7 in the mITT population. A total of 100 participants completed the study, for which the scores of the last dose used were calculated.